Assess the patient's lesions to identify those visually suggestive of skin cancer for which an objective risk assessment would be helpful.
Use DermaSensor to analyze those lesions of concern to receive a Higher Risk or Lower Risk result for each lesion.
Counsel your patient on next steps, such as further investigating the lesion through a biopsy or specialist referral, or just monitoring the lesion having ruled out the need for an immediate biopsy or referral.
Safety and Efficacy Results for DERM-ASSESS II Prospective, Multi-Centre Study
Study reported no adverse events as well as no significant difference between DermaSensor's and dermatologists' sensitivity and specificity
DermaSensor's sensitivity for melanoma was 100.0%* while the study dermatologists' was 90.9%. For BCC and SCC, also known as Non-Melanoma Skin Cancer (NMSC), DermaSensor's sensitivity was 93.3% and the dermatologists' was 98.3%
DermaSensor Device and Dermatologist Sensitivity For Skin Cancers
False-positive and false-negative results may lead to unnecessary care or to a malignant skin lesion not being optimally managed, respectively. However, it is important to note that biopsy is used to confirm pathology and that elastic scattering spectroscopy is to be used as an adjunctive tool to visual inspection and history-taking. See all Claims and Substantiations